Floatz logo

Irradiated Allogeneic Cells

Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Rutgers, The State University of New JerseyCell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
ETOPOSIDE
Alliance for Clinical Trials in Oncology
Phase 4BB
DEXAMETHASONE
Zhengzhou University
Phase 4BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2BB
FILGRASTIM
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

Irradiated Allogeneic Cells is also rated in:

acute myeloid leukemiaDormant
C
Indicative ·
39 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
C
Indicative ·
39 / 100
View asset →
myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2Dormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →